Precision Technology Drives $594B Cancer Drug Market Growth

The cancer drugs market is projected to reach a staggering $594.3 billion by 2035, largely due to the rise of precision technologies and advanced immunotherapies that are gradually replacing traditional chemotherapy. This growth trajectory marks a turning point in how cancer is treated, especially with the emergence of therapies that can activate a patient’s immune system to combat cancer more effectively.

As of now, response rates for some previously untreatable blood cancers have soared to over 90%. This remarkable success is driving investment interest in companies such as Oncolytics Biotech Inc. (NASDAQ:ONCY), BriaCell Therapeutics Corp. (NASDAQ:BCTX) (TSX:BCT), Greenwich LifeSciences, Inc. (NASDAQ:GLSI), Citius Oncology (NASDAQ:CTOR), and Kazia Therapeutics Limited (NASDAQ:KZIA). The metastatic cancer treatment sector alone is already valued at $84.66 billion, with precision therapies holding a commanding 54.51% market share.

Oncolytics Biotech is advancing its investigational immunotherapy, pelareorep, which shows promise in treating various forms of cancer. Recent data revealed that pelareorep achieved a 33% objective response rate when combined with standard chemotherapy in patients with second-line KRAS-mutant microsatellite-stable metastatic colorectal cancer. This is a significant improvement compared to the historical response rate of 6-11% for chemotherapy alone, especially in a market expected to grow to $20 billion by 2033.

The results for anal cancer are equally encouraging, with a 30% response rate reported in patients with second-line squamous cell anal carcinoma, more than doubling the existing benchmark of 13.8% for the only FDA-approved treatment in this area. The median duration of response was also impressive, lasting 15.5 months compared to 9.5 months for standard care.

To solidify its research credibility, Oncolytics Biotech has bolstered its Gastrointestinal Tumor Scientific Advisory Board by adding three prominent oncologists: Dr. Eileen O’Reilly, Dr. Neil Segal, and Dr. Van Morris. Dr. Morris, who serves as Section Chief for Colorectal Cancer at MD Anderson Cancer Center, expressed confidence in the potential of pelareorep, emphasizing the need for further studies to explore its efficacy in gastrointestinal cancers.

Oncolytics Biotech has also gained FDA alignment for its Phase 3 study design involving pelareorep as a first-line treatment for metastatic pancreatic cancer. This positions the company for a potentially groundbreaking immunotherapy registration trial in this area, with pelareorep already holding Fast Track and Orphan Drug designations from the FDA.

The leadership team at Oncolytics, including CEO Jared Kelly and Chief Business Officer Andrew Aromando, has a history of navigating clinical assets through successful transactions, exemplified by their roles in Ambrx Biopharma’s $2 billion acquisition by Johnson & Johnson.

In broader industry developments, BriaCell Therapeutics Corp. recently shared promising results from its Phase 3 Bria-ABC study at the 2025 San Antonio Breast Cancer Symposium. The study indicates that specific biomarkers might predict clinical responses in metastatic breast cancer patients treated with the Bria-IMT regimen combined with checkpoint inhibitors. Notably, the interim analysis of 116 patients showed favorable progression-free survival rates for those with HR+/HER2- and HER2-Low disease.

Meanwhile, Greenwich LifeSciences, Inc. reported that its Phase III FLAMINGO-01 trial, which evaluates GLSI-100 for preventing breast cancer recurrences, showed an approximate 80% reduction in recurrence rates. The study has fully enrolled 250 patients and continues to expand its reach, with plans for additional sites in the UK and Canada.

Citius Oncology marked a significant milestone by launching LYMPHIR in the U.S. for treating adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma. This new treatment option is expected to capture an initial market exceeding $400 million.

Kazia Therapeutics Limited presented new findings that highlight the effectiveness of paxalisib, a dual PI3K/mTOR inhibitor, in disrupting aggressive circulating tumor cell clusters in HER2-positive and triple-negative metastatic breast cancer. The results indicate significant reductions in tumor volume and circulating tumor cells, suggesting a transformative potential for the drug in enhancing immunotherapy outcomes across multiple breast cancer subtypes.

As the cancer treatment landscape evolves, the integration of precision technologies and immunotherapies is reshaping patient outcomes, opening new avenues for treatment, and driving substantial market growth. The ongoing research and development efforts from these companies underscore a concerted commitment to overcoming the challenges posed by metastatic cancers.